-Curebound, a philanthropic organization that raises and invests strategic funding for cancer research, is announcing important updates on its grant reci...
Investment in Oxford Nanopore, innovators of a transformational new generation of sensing technology that today specialises in DNA/RNA sequencing &pou...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to acceler...
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Par...
Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Mill...
CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...
Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
Myocene, the Liège-based sportstech company developing a unique, cutting-edge device to objectively measure muscle fatigue, announced that i...
Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, fo...
AB-BIOBETTER, led by Bio-Sourcing, to pioneer development of new oral formulation of adalimumab for inflammatory bowel diseases; offering patient...
© 2024 Biopharma Boardroom. All Rights Reserved.